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Summary Canine transmissible venereal sarcoma (CTVS) is a naturally occurring contagious neoplasm
which can be transplanted with intact viable cells across major histocompatibility (MHC) barriers within the
species and even to other members of the canine family, such as foxes, coyotes, and wolves. After 2 to 4
months of progressive growth the tumour regresses spontaneously in adults but metastasizes in immuno-
suppressed hosts and neonates. The mechanisms of how the tumour cells manage to overcome histo-
compatibility barriers so successfully for such a long period and yet succumb later are not known. In the
present study we found that CTVS cells were not stimulatory to the lymphocytes of normal or tumour-
bearing animals in mixed lymphocyte-tumour reaction (MLTR), although the lymphocytes from tumour-
bearing hosts responded well to either phytohaemagglutinin (PHA) or third-party allogeneic lymphocytes.
Immunofluorescent antibody (IFA) assay of MHC antigens by monoclonal antibodies (MoAb) to mono-
morphic Class I and Class II MHC antigens showed that progressor tumour cells lacked the expression of the
antigens whereas 30 to 40% of regressor tumour cells expressed them.
Canine transmissible venereal sarcoma (CTVS) is probably which most CTVS cells were not viable following collagenese
the only known instance of natural, successful trans- digestion.
plantation of allogeneic cells (Moulton, 1978; Gross, 1983; The tumour grows equally in both males and females and
Cohen, 1985). It is transmitted via intact viable cells as a thus dogs of both sexes were used in the experiment.
stem-line through coition among dogs of various parts of the Collagenase (Grade 1, Sigma Chemicals Co., St. Louis,
world (Makino, 1963; Weber et al., 1965). After 2 to 4 MO, USA) dissociated tumour cells in 0.02% sodium azide
months of progressive growth, the tumour regresses spontan- were used in immunofluorescent (IF) assay for membrane
eously in adults but metastasizes in immunosuppressed dogs antigens whereas cells from tumours minced with scissors
(Cohen, 1973) and neonates (Yang & Jones, 1973). The were used in mixed lymphocyte-tumour reaction (MLTR)
mechanisms of how the tumour cells manage to overcome studies. Both progressor and regressor tumour cells were
histocompatibility barriers so successfully for such a long used in IF assay but, due to the difficulty in obtaining
period and yet succumb later are not known. enough cells from regressors, only progressor tumours were
In this communication we present evidence that lack of used in MLTR.
expression of major histocompatibility complex (MHC) anti- For MLTR assay, mechanically dispersed CTVS cells were
gens may be responsible, at least in part, for 'universal take' washed four to five times and suspended to 1 to 5 x 107
and progressive growth of CTVS in allogeneic hosts. cellsml- in 7 to 10ml of Hanks' balanced salt solution
(HBSS). The suspension (5ml) was layered over a linear
Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden)
Materials and methods density gradient, modified from that described by Ulmer &
Flad (1979). For preparation of the gradient, 9ml of Percoll
Tumour cells was mixed with 1 ml of lOX HBSS, pH 5.0, and made into a
linear gradient with 1X HBSS, pH7.4. The densities of the A naturally occurring CTVS was the source of the tumour .gradient rage fo 1.06 gml4 To 1.12igiml
ofthe
cells used for the laboratory transplantations. At passagegrad,ent ranged from 1.06gml-I to 1.12gml-1. The
animals(oth e adf ) we i d s.c.in te gradient with layered cells was centrifuged at 390g for
interscapular region with 5 to 10x 107 trypan-blue-excluding 30mn at room temperature. Five bands of cells formed ntu pularcelsg(Yng & Jones, 1973). T growth of the within the gradient and the third band contained pre- nemoplasms ws measure inee peren.diua drection t dominantly viable tumour cells. This band of cells was neoplasms was measured in three perpendiculardi. as harvested, washed, and cytocentrifuge smears of these and weekly or twice weekly intervals. The tumour volume was all cell suspensions were made.
determined by the equation:
V=
- h Mixedlymphocyte reaction (MLR) and mixedlymphocyte
4 tumour reaction (MLTR)
where V=volume (cm3); I=length (cm); w=width (cm); and Mitomycin C-treated lymphocytes and CTVS cells were used
h=thickness (cm). as stimulators in one-way MLR and MLTR, respectively. In
The growth patterns of the tumour were classified addition, appropriate controls such as mitomycin-C treated
'progressor', a tumour that was steadily increasing in responder cells were also included.
volume; 'steady state', a tumour that was neither increasing For mitomycin C (MC) treatment, lymphocytes (2 x 106
or decreasing significantly in volume; 'early regressor', a cellsml-1) and tumour cells (1 x 106cellsml 1) were treated
tumour that was decreasing rapidly in volume andl in which with 25ygml 1 of MC (Sigma), according to the protocol of
most CTVS cells were viable following collagenase digestion; Waithe & Hirschorn (1973).
and 'late regressor', a tumour in which the volume was For the assays, responder cells from tumour-bearing
decreasing slowly following a period of rapid decline in animals and controls were added to stimulator cells at a 1:1 ratio for peripheral blood lymphocytes and 2:1 ratio for
lymph node cells. Appropriate control cultures were estab-
Correspondence: T.J. Yang. lished with the same cell ratios. After incubation of mixed
Received6August 1986;andinrevisedform70October 1986. cultures at 37°C for 6 days they were pulsed with 3[H]-132 T.J. YANG et al.
thymidine for 14 to 16h and processed for scintillation the draining (prescapular) (Table II) lymph node cells of
counting. The mitogen response of lymphocytes was assayed tumour-bearing dogs. There was, however, a slight
by adding phytohaemagglutinin-P (PHA-P) and processed stimulatory effect of tumour cells on normal lymphocytes
similarly. (SI 4.3).
In contrast, the lymphocytes from the peripheral blood
Class I and Class II MHC antigen assays and draining lymph nodes of tumour dogs reacted equally or
Anti-human monoclonal antibody (MoAb) 7.2 which also nearly so, respectively, as those of normal dogs in the third-
reacts with monomorphic canine Class 1I antigens was a gift party MLR (Table II) and PHA cultures.
from Dr John A. Hansen of the Fred Hutchinson Cancer Class I and Class II MHC antigen expression
Research Center, Seattle, WA., USA (Hansen et al., 1980;
Deeg et al., 1982) and MoAb 3F10 (Eisenbarth et al., 1980) As shown in Table III, progressor tumours lacked the
which reacts also with monomorphic canine Class I antigens expression of Class I MHC antigens detectable with anti-
(Yang et al., manuscript in preparation) was a gift from Drs monomorphic Class I MoAb 3F10 which detected such
Barton F. Haynes and Thomas J. Palker of Duke University. antigens on all of normal lymph node cells and 18% of
An indirect IF technique employing biotin-avidin system was normal thymocytes. Similarly, progressive tumours lacked
used for identifying membrane antigens. Briefly, collagenase- the expression of Class II MHC antigens detectable with
dissociated CTVS cells were washed and resuspended in anti-monomorphic Class II MoAb 7.2 which detected such
1 x 107cellsml-l in fluorescent antibody buffer (FAB) antigens on 35% of normal lymph node cells and 7% of
consisting of 1% bovine serum albumin (BSA) and 0.02% normal thymocytes.
sodium azide in phosphate (0.15M) buffered saline (PBS), In contrast, 32 to 36% of early regressor tumour cells (late
pH 7.2. Only cell suspensions with over 85% viable cells were regressor tumours had lower cell viability and thus were not
used. CTVS cell suspensions (100Ml) were mixed with 0.1ml
of 1:50 dilution of MoAb 7.2 or MoAb 3F10. The cells were
incubated for 30min in an ice bath, washed three times, and Table III Expression of monomorphic Class I and Class II
the cell pellet added with 0.1 ml of a 1:300 dilution of MHC antigens by canine transmissible venereal sarcoma biotinylated horse anti-mouse IgG (heavy and light chains (CTVS) and normal canine lymphoid cells
specific; Vector Laboratories, Burlingame, CA, USA), in-
cubated, washed, and resuspended in 0.1 ml of a 1:300 MHC antigens (% positive)
dilution of fluorescein isothiocyanate (FITC)-conjugated
avidin (Vector). After incubation for 30min in an ice bath Tissues Class P Class Ilb
and washed three times, the cells were examined under the
microscope and 200 cells were counted. Progressor tumourc (n =8) 0 0 Regressor tumourc (n=6) 31.5+9.4 36.4+8.5
Lymph node (n =4) 98.4+ 1.4 34.7+6.3
Thymus(n=4) 17.9+4.0 6.5+2.9
Results
aDetermined with anti-monomorphic Class I MoAb 3F10
Mixed lymphocyte tumour reaction (MLTR) and mixed by avidin-biotin-FITC indirect membrane immunofluores-
lymphocyte reaction (MLR) cence (IF); bDetermined with anti-monomorphic Class II
MoAb 7.2 by IF; cTumour cells only. They were much larger As shown in Tables I and II, CTVS cells were not (>15jm) than the infiltrating leucocytes (mostly lympho-
stimulatory to the peripheral blood lymphocytes (Table I) or cytes, <8pu).
Table I Mixed lymphocyte-tumour reaction (MLTR)' and mixed lymphocyte reaction (MLR)b of peripheral blood lymphocytes
from normal and canine transmissible venereal sarcoma (CTVS)-bearing hosts
MLTR (CPM) MLR (CPM)
Experimental Control A SP Experimental Control A SI
Normal (n =5) 1,636+562 379+ 178 1,260+ 384a 4.3 7,684+ 1,957 485+229 7,200+1,728d 16
Progressors (n =7) 738+ 133 522+111 220+ 22b 1.4 9,344_4,203 474+111 8,900±4,092e 20
Regressors (n=5) 729+160 339+136 390+ 24C 2.2 4,978+3,250 357+170 4,600+3,080f 14
aOne-way MLTR with mitomycin C-treated CTVS cells; bOne-way MLR with mitomycin C-treated third-party normal canine
(No. 75) lymphocytes; cStimulation index=CPM of experimental culture/CPM of control culture. Student's t-test showed: a versus
b P<0.001; a versus c P<0.01; d versus e not significant (NS); d versusf(NS); d versus a P<0.01; e versus b P<0.01; f versus c
P<0.01.
Table II Mixed lymphocyte-tumour reaction (MLTR)' and mixed lymphocyte reaction (MLR)b of draining
(prescapular) lymph node cells from normal and canine transmissible venereal sarcoma (CTVS)-bearing hosts
MLTR (CPM) MLR (CPM)
Experimental Control A Slf Experimental Control A SI
Normal (n=5) 443+220 422+238 229 1.0 18,205± 708 514+312 17,700' 35
Progressors(n=7) 501+131 286+ 84 215h 1.8 10,972±1,066 451+ 89 1O,S00k 24
Regressors (n=5) 249+ 35 255+ 90 -6 1.0 7,336±+3,923 362+ 182 7,0001 20
aOne-way MLTR with mitocycin C-treated CTVS cells; bOne..way MLR with mitomycin C-treated third-party
normal canine (No. 75) lymphocytes; cStimulation index=CPM of experimental culture/CPM of control culture.
MLTR among groups not significant; MLR versus MLTR within groups (gIl; h/k; i/l) are all significantly different
at P<0.01.MHC ANTIGEN EXPRESSION ON CANINE SARCOMA 133
used) expressed Class I antigen and Class II antigens,
respectively. The tumour cells were much larger (>15gm)
than the infiltrating leucocytes (mostly lymphocytes, <8 ,um),
and did not express surface immunoglobulins or T-cell
antigens in the parallel direct and indirect IF assays (Trail &
Yang, 1985). The number of MHC Class I and Class II
antigen positive cells remained the same after overnight
culture, indicating that they were expressed, and not
adsorbed, antigens.
Discussion
Impressed by the intriguing theoretical problems posed by
this tumour (the canine transmissible venereal sarcoma), the
late Dr P.A. Gorer suggested in 1960 that 'were it not for
the antigenic diversity of most species and the existence of a
mechanism to react against the antigen, contagious tumors
would be relatively common' (Beer & Billingham, 1976). In
this experiment we presented evidence to support that CTVS
is indeed the experiment of nature for a successful
mammalian cell parasite. The progressively growing CTVS
cells were not stimulatory to the lymphocytes from tumour-
bearing (secondary response) and normal (primary response)
hosts in MLTR. In contrast, lymphocytes from the
peripheral blood and the draining lymph nodes of tumour-
bearing animals reacted equally, or nearly so, as those of
normal controls in the third-party MLR (Table II) and PHA
cultures.
Immunofluorescent assay of Class I and Class II MHC
antigens with monomorphic antigen specific MoAbs
indicated that MLTR non-reactivity is due, in part at least,
to the lack of expression of Class II antigens in progressor
tumours. However, 36% of tumour cells from regressor
tumours did express Class II antigen although the failure to
stimulate in MLTR may be attributable to many factors
other than lack of MHC antigen expression.
This possibility is reflected, in part, by the finding of
higher MLTR reactivity with peripheral blood lymphocytes
of normal dogs (SI 4.3; Table I) than that of tumour bearing
animals (SI 1.6 for progressor; 1.4 for regressor; Table I) due
probably to stimulatory effect of tumour infiltrating allo-
geneic lymphocytes (<10%; Chandler & Yang, 1981) rather
than tumour cells per se. Although we have attempted to
'free' infiltrating lymphocytes from the tumour cell sus-
pension by Percoll density gradient separation, traces of such
cells might have been left to stimulate allogeneic normal
canine lymphocytes. No such reaction occurred in tumour
dog MLTR for reasons unknown or in progressors, at least,
the residual tumour infiltrating host lymphocytes were auto-
logous although the tumours were allogeneic. In the experi-
ments of Hess et al. (1975), they did not consider that
contaminating lymphocytes were responsible and the
contrasting results remain an enigma.
Our findings on the lack of expression of Class I antigens
(Table III) on progressor tumours confirm and substantiate
the finding of Cohen et al. (1984) who showed that CTVS
cells lack fl2-microglobulin expression. Since expression of
the a chains of Class I antigens on the cell surface depends
on the presence of /32-microglobulins, we do not know
whether the lack of expression of Class I antigens on CTVS
is due to the absence of a chain product and/or f2-
microglobulin. In contrast, 32% of regressor tumour cells
were Class I antigen positive, confirming the results of
Epstein & Bennett (1974) who studied the CTVS cell lines
obtained from Dr D. Cohen. The difference in results
obtained by Cohen et al. (1984) and Epstein & Bennett
(1974) from the same lines of CTVS cells remains unknown.
The polymorphic phenotypes of the Class I and Class II
MHC antigens which are expressed on regressing CTVS need
to be investigated further.
Although CTVS cells have been shown previously to be
coated with immunoglobulin during the progressive phase of
tumour growth (Cohen, 1972; Bennett et al., 1975;
Beschorner et al., 1979), the collagenase-dissociated and
washed tumour cells used in this study were found to be free
of immunoglobulin coating as assayed by immuno-
fluorescence assay, indicating that the failure to demonstrate
MHC antigens on progressively growing tumours was not
due to masking of tumour cells with immunoglobulins.
We feel that lack of expression of Class I and Class II
MHC antigens on progressor tumour cells as shown in this
study, shedding of tumour-associated antigen (Palker &
Yang, 1981; Palker et al., 1986 [manuscript in preparation]),
formation of immune complexes (Palker & Yang, 1985), and
production of blocking factors (Bennett et al., 1975;
Beschorner et al., 1979) may be mechanisms responsible for
CTVS to escape recognition (Beer & Billingham, 1976) and
to block hosts' immune system (Alexander, 1974; Harding &
Yang, 1985) and grow progressively in allogeneic hosts. In
contrast, as substantiated by recent experimental demonstra-
tion of reversal of oncogenesis by the expression of MHC
Class I gene in adenovirus-12 transformed mouse cells
(Tanaka et al., 1985), expression of Class I and Class II
MHC antigens on regressor tumour cells observed in this
study and the changes in tumour cell types from round to
spindle-shaped 'transitional' cells (Kennedy et al., 1977; Hill
et al., 1984) suggest that induction of cell differentiation by
the product (e.g. lymphokines) of infiltrating lymphocytes
(Yang et al., 1976), especially T-cells (Chandler & Yang,
1981; Trail & Yang, 1985) may be important in spontaneous
tumour regression.
This investigation was supported by Grant CA 23469 awarded by
the National Cancer Institute, DHHS. We thank Dr John A.
Hansen of Fred Hutchinson Cancer Research Center and Drs
Barton F. Haynes and Thomas J. Palker of Duke University for
monoclonal antibodies used in this study. We thank Miss Patricia
Timmins for preparation of the manuscript.
References
ALEXANDER, P. (1974). Escape from immune destruction by the
host through shedding of surface antigens: Is this a characteristic
shared by malignant and embryonic cells? Cancer Res., 34, 2077.
BEER, A.E. & BILLINGHAM, R.E. (1976). A transmissible venereal
tumor in the dog. In The Immunobiology of Mammalian Repro-
duction, p. 105. Prentice-Hall: Englewood Cliffs, N.J.
BENNETT, B.T., DEBELAK-FEHIR, K.M. & EPSTEIN, R.B. (1975).
Tumor blocking and inhibitory serum factors in the clinical
course of canine venereal tumor. Cancer Res., 35, 2942.
BESCHORNER, W.E., HESS, A.D., NURENBERG, S.T. & EPSTEIN, R.B.
(1979). Isolation and characterization of canine venereal tu,mor-
associated inhibitory and blocking factors. Cancer Res., 39, 3920.
CHANDLER, J.P. & YANG, T.J. (1981). Canine transmissible venereal
sarcoma: distribution of T and B lymphocytes in blood, draining
lymph nodes, and tumours at different stages of growth. Br. J.
Cancer, 44, 514.
COHEN, D. (1972). Detection of humoral antibody to the trans-
missible venereal tumour of the dog. Int. J. Cancer, 10, 207.
COHEN, D. (1973). The biological behaviour of the transmissible
venereal tumour in immunosuppressed dogs. Eur. J. Cancer, 9,
253.
COHEN, D. (1985). The canine transmissible venereal tumor: A
unique result of tumor progression. Adv. Cancer Res., 43, 75.
COHEN, D., SHALEV, A. & KRUP, M. (1984). Lack of /2-
microglobulin on the surface of canine transmissible venereal
tumor cells. J. Natl Cancer Inst., 72, 395.
DEEG, H.J., WULFF, J.C., DEROSE, S. & 6 others. (1982). Unusual
distribution of Ia-like antigens in canine lymphocytes. Immuno-
genetics, 16, 445.134 T.J. YANG et al.
EISENBARTH, G.S., HAYNES, B.F., SCHROER, J.A. & FAUCI, A.S.
(1980). Production of monoclonal antibodies reacting with
peripheral blood mononuclear cell surface differentiation
antigens. J. Immunol., 124, 1237.
EPSTEIN, R. & BENNETT, B.T. (1974). Histocompatibility typing and
course of canine venereal tumors transplanted into unmodified
random dogs. Cancer Res., 34, 788.
GROSS, L. (1983). The contagious venereal dog sarcoma. In
Oncogenic Viruses, Vol. 1, p. 117. Pergamon Press: New York.
HANSEN, J.A., MARTIN, P.K. & NOWINSKI, R.C. (1980). Monoclonal
antibodies identifying a novel T-cell antigen and Ia antigen of
human lymphocytes. Immunogenetics, 10, 247.
HARDING, M.W. & YANG, T.J. (1985). Regulation of leukocyte glass
adherence and tube leukocyte adherence inhibition (LAI)
reactivity by serum factors in dogs with progressing or spontan-
eously regressing canine transmissible venereal sarcoma (CTVS).
Cancer Immunol. Immunotherap., 19, 168.
HESS, A., CUNNINGHAM, B., BENNETT, B.T. & EPSTEIN, R. (1975).
In vitro correlates of the in vivo course of the canine transmissible
venereal tumor studied by mixed lymphocyte tumor culture.
Transplantation Proc., 7, 507.
HILL, D.L., YANG, T.J. & WACHTEL, A. (1984). Canine transmissible
venereal sarcoma: tumor cell and infiltrating leukocyte ultra-
structure at different growth stages. Vet. Pathol., 21, 39.
KENNEDY, J.R., YANG, T.J. & ALLEN, P.L. (1977). Canine trans-
missible venereal sarcoma: electron microscopic changes with
time after transplantation. Br. J. Cancer, 36, 375.
MAKINO, S. (1963). Some epidemiological aspects of venereal
tumors of dogs as revealed by chromosome and DNA studies.
Ann. N.Y. Acad. Sci., 108, 1106.
MOULTON, J.E. (1978). Transmissible venereal tumor of the dog. In
Tumors in Domestic Animals, p. 326. University of California
Press: Berkeley.
PALKER, T.J. & YANG, T.J. (1981). Identification and physico-
chemical characteristics of a tumor-associated antigen from
canine transmissible venereal sarcoma. J. Natl Cancer Inst., 66,
779.
PALKER, T.J. & YANG, T.J. (1985). Detection of immune complexes
in sera of dogs with the canine transmissible venereal sarcoma
(CTVS) by a conglutinin binding assay. J. Comp. Pathol., 95,
247.
TANAKA, K., ISSELBACHER, K.J., KHOURY, G. & JAY, G. (1985).
Reversal of oncogenesis by the expression of a major histo-
compatibility complex Class I gene. Science, 228, 26.
TRAIL, P.A. & YANG, T.J. (1985). Canine transmissible venereal
sarcoma: quantitation of T-lymphocyte subpopulations during
progressive growth and spontaneous tumor regression. J. Natl
Cancer Inst., 74, 461.
ULMER, A.J. & FLAD, H.D. (1979). Discontinuous density separation
of human mononuclear leukocytes using Percoll as gradient
medium. J. Immunol Methods, 30, 1.
WAITHE, W.J. & HIRSCHORN, K. (1973). Lymphocyte response to
activators. In Handbook of Experimental Immunology, Vol. 2,
Cellular Immunology, D.M. Weir (ed), p. 25. Blackwell Scientific
Publications: London.
WEBER, W.T., NOWELL, P.C. & HARE, W.C.D. (1965). Chromosome
studies of a transplanted and a primary canine venereal sarcoma.
J. Natl Cancer Inst., 35, 537.
YANG, T.J. & JONES, J.B. (1973). Canine transmissible venereal
sarcoma: transplantation studies in neonatal and adult dogs. J.
Natl Cancer Inst., 51, 1915.
YANG, T.J., ROBERTS, R.S. & JONES, J.B. (1976). Quantitative study
of lymphoreticular infiltration into canine transmissible venereal
sarcoma. Virchow's Arch., B. Cell. Pathol., 20, 197.